Trial Profile
Open-label Study of Safety and Tolerability of Chronic Intermittent Usage for 24 or 52 Weeks of Intranasal Dihydroergotamine Mesylate (DHE) Administered Using the I123 Precision Olfactory Delivery (POD) Device [INP104, POD-DHE] in Patients With Migraine Headache
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs Dihydroergotamine mesilate (Primary)
- Indications Migraine
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms STOP-301
- Sponsors Impel Pharmaceuticals
- 15 Jun 2023 According to an Impel Pharmaceuticals media release, data from this study will be presented at the 65th Annual Scientific Meeting of the American Headache Society (AHS), taking place June 15-18, 2023, in Austin, Texas.
- 27 Apr 2023 Results of a post-hoc analysis over 24 weeks presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 27 Apr 2023 Results (n=354) assessing the safety in migraine patients who used a triptan within 24 hours of INP104 administration, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.